Elsevier

European Journal of Medicinal Chemistry

Volume 73, 12 February 2014, Pages 280-285
European Journal of Medicinal Chemistry

Short communication
20S proteasome as novel biological target for organochalcogenanes

https://doi.org/10.1016/j.ejmech.2013.12.011Get rights and content

Highlights

  • 20S proteasome inhibition by hypervalent chalcogen compounds was studied.

  • Organoselenuranes and organotelluranes in cellular assays were evaluated.

  • Organotelluranes were identified as more potent inhibitors than organoselenanes.

  • High inhibitory potency and specificity toward the β2 catalytic site was observed.

Abstract

A series of hypervalent selenium- and tellurium-containing compounds (organoselenuranes and organotelluranes) was evaluated aiming novel inhibitors of a threonine protease, namely the 20S proteasome (20S PT). In vitro assays demonstrated high inhibitory potency and specificity of these compounds toward the β2 catalytic site of the 20S PT. Organotelluranes were identified as more potent inhibitors than organoselenuranes since their IC50 ranged from 3.5 to 16 μM while for organoselenuranes the IC50 ranged from 16 to 35 μM indicating great potential to be explored in 20S proteasome inhibition. Cellular assays with those compounds were employed to verify the cytotoxicity and ability to inhibit 20S proteasome in cell. These assays demonstrated that organoselenuranes are capable of maintaining their selectivity in cell while the organotelluranes became inactive under cellular conditions. Stability studies of the organochalcogenanes were performed by 77Se and 125Te NMR analysis. It was observed that organotelluranes are stable under enzymatic assay conditions and, organoselenuranes, the structures responsible for inhibitory activity are cyclized organoselenuranes.

Introduction

Biological investigations on selenium- and tellurium-containing compounds have increased in last decade. These compounds were thought to be deleterious but, recent studies have been proven otherwise and beneficial pleiotropic activities have been described. Antioxidative (as GPx mimetics) [1], anti-inflammatory [2], [3], neuroprotective [4], cancer prevention [5], pro-apoptotic [6] and immunomodulatory activities [7] are some of the biological properties described for selenium and tellurium-containing compounds. And that includes structure-based design of small molecules as enzyme inhibitors such as calpains, papain, cathepsins, protein tyrosine phosphatases [8]. The biological response for selenium- and tellurium-containing compounds commonly relies on an interaction with some sulfhydryl enzymes [9]. Pioneering demonstrated that inorganic telluranes are able to inhibit thiol-dependent enzymes but are inactive against oxygen-nucleophilic (O-nucleophilic) proteases (e.g. serine proteases) [10]. After that, the potential of chalcogenanes (organic and inorganic) has focused on thiol-dependent enzymes. Even when it was demonstrated that organotelluranes are more reactive species (more powerful inhibitors of thiol-dependent proteases) [11] than inorganic ones the possible activity of organotelluranes (and organoselenuranes) against other proteases was not explored. In this way, we decided to explore these possibilities, by demonstrating that organoselenuranes are capable of inhibiting cysteine cathepsins, a thiol-dependent proteases family [12] and we also established the structure–activity relationships involving both organoselenuranes and organotelluranes and cysteine cathepsins V and S [13]. Based on ours previous reports, we have considered the possibility that chalcogenated organic compounds can inhibit another class of protease, since, as aforementioned, only inorganic telluranes were evaluated against serine proteases [10]. To the best of our knowledge, interactions of selenium- and tellurium-containing organic compounds with non-thiol-dependent proteases are yet unknown. For that, we chosen as target the proteasome, a threonine protease (O-nucleophilic protease) which is responsible for all non-lysosomal cellular proteolysis in cell [14]. This enzyme is a multi-catalytic protease with a proteolytic core (20S proteasome, 20S PT), which contains three catalytic sites (β1, β2 and β5), each one presenting a nucleophilic N-terminus threonine residue [15]. The catalytic sites have different specificities: β1 presenting a caspase-like activity, β2 trypsin-like activity and β5 chymotrypsin-like activity [16]. This protease is involved in the most of intracellular processes of eukaryotic cells such as signal transduction, immune response, metabolism, cell death, besides protein turnover for cell quality control and regulatory purposes [17]. The most important proteasome inhibitors described in the literature can be divided into 5 classes: peptide aldehydes, peptide vinyl sulfones, peptide boronates, peptide epoxyketones and β-lactones [18]. Moreover, these inhibitors present unsuitable properties for future clinical investigation [19] and new classes of compounds capable of inhibiting proteasome are still required. In view of the importance of 20S PT and a lack of a study of organic selenium and tellurium compounds with thiol-independent proteases, we decided to explore the reactivity of organoselenuranes and organotelluranes (Fig. 1) against an O-nucleophilic protease (20S PT).

Section snippets

Results and discussion

The preparation of the organochalcogenanes 112 and their precursors was carried out from 1-phenylethanol derivatives as described previously [8].

The inhibitory profiles of organochalcogenanes against β1-caspase-like, β2-trypsin-like and β5-chymotrypsin-like sites of the mammalian 20S proteasome were determinated by an in vitro assay using 100 μmol L−1 of the compounds. The enzyme assays demonstrated that organochalcogenanes 112 are inactive against β1 and β5 sites (Fig. 2B and C). On the

Conclusions

The present results revealed that organochalcogenanes are a new class of 20S proteasome inhibitors, with an unusual high specificity to the β2 – trypsin-like catalytic site. Moreover, the organotelluranes presented superior potency in a close nanomolar scale (5–16 μM) than congeners, organoselenuranes. In cellular assays it was demonstrated that organoselenuranes are capable of maintaining efficiently their selectivities in inhibiting the β2 site, while organotelluranes became inactive under

Acknowledgment

The authors thank CNPq, CAPES and FAPESP for their financial support. The authors thank R. L. O. R. Cunha for helpful discussions.

References (20)

  • M. Brodsky et al.

    J. Inflamm.

    (2010)
  • A. Carmely et al.

    Hum. Reprod.

    (2009)
  • L. Piovan et al.

    Org. Biomol. Chem.

    (2011)
    I.E. Gouveia et al.

    Biol. Chem.

    (2011)
    M. Abdo et al.

    J. Am. Chem. Soc.

    (2008)
  • L. Piovan et al.

    Bioorg. Med. Chem.

    (2011)
  • L. Borrisenko et al.

    Chem. Rev.

    (2007)
  • M. McNaughton et al.

    J. Med. Chem.

    (2004)
    T. Kanda et al.

    J. Org. Chem.

    (1999)
    E. Wieslander et al.

    Biochem. Pharmacol.

    (1998)
  • L.H. Duntas

    Horm. Metab. Res.

    (2009)
    K.P. Bhabak et al.

    Chem. Asian J.

    (2009)
  • D.S. Persike et al.

    Neurobiol. Dis.

    (2008)
    S. Pinton et al.

    Neurosci. Lett.

    (2010)
  • G.N. Schrauzer

    Crit. Rev. Biotechnol.

    (2009)
    U. Gundimeda et al.

    Carcinogenesis

    (2009)
    J. Fleming et al.

    Nutr. Cancer

    (2001)
    H.E. Ganther

    Carcinogenesis

    (1999)
    G.F. Combs et al.

    Pharmacol. Ther.

    (1998)
  • C. Sanmartin et al.

    Mini-Rev. Med. Chem.

    (2008)
    R. Sinha et al.

    Curr. Cancer Drug Target

    (2004)
    N. Zhou et al.

    J. Biol. Chem.

    (2003)
There are more references available in the full text version of this article.

Cited by (25)

  • Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome

    2015, European Journal of Medicinal Chemistry
    Citation Excerpt :

    Therefore, it is imperative to search for novel non-covalent proteasome inhibitors as potential chemotherapeutic agents. Up to now, peptide-based proteasome inhibitors remain to be the mainstream in this field [5], although peptidomimetic [6], pseudopeptide-based [7] and non-peptidic [8–10] inhibitors have been recently reported. TMC-95A (Fig. 1a) is a natural cyclic tripeptide isolated from fermentation broth of the ascomycete fungus Apiospora montagnei [11].

View all citing articles on Scopus
1

Present address: Departamento de Química, Universidade Federal do Paraná, Centro Politécnico – 81531-980, Curitiba, Brazil.

View full text